Ventyx Biosciences
Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Ventyx’s clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions.
Domain
ventyxbio.com
Country
United StatesIndustry
BiopharmaEmployees
101-250
Last Funding
$27.0M
Founded
2017
Frequently Asked Questions
What technologies does Ventyx Biosciences use?+
Ventyx Biosciences uses 2 technologies including Flywheel, WordPress.
What industry is Ventyx Biosciences in?+
Ventyx Biosciences operates in the Biopharma industry.
Where is Ventyx Biosciences based?+
Ventyx Biosciences is headquartered in United States.
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026